There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Outset Medical (OM – Research Report), Biofrontera (BFRI – Research Report) and 2seventy bio (TSVT – Research Report) with bullish sentiments.
Outset Medical (OM)
RBC Capital analyst Shagun Singh Chadha reiterated a Buy rating on Outset Medical today and set a price target of $29.00. The company’s shares closed last Monday at $20.16.
According to TipRanks.com, Chadha is a 3-star analyst with an average return of
The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Outset Medical with a $28.00 average price target.
See the top stocks recommended by analysts >>
Biofrontera (BFRI)
Benchmark Co. analyst Bruce Jackson reiterated a Buy rating on Biofrontera today and set a price target of $7.00. The company’s shares closed last Monday at $0.41, close to its 52-week low of $0.37.
According to TipRanks.com, Jackson is ranked 0 out of 5 stars with an average return of
Currently, the analyst consensus on Biofrontera is a Moderate Buy with an average price target of $7.00.
2seventy bio (TSVT)
Wedbush analyst David Nierengarten reiterated a Buy rating on 2seventy bio today and set a price target of $26.00. The company’s shares closed last Monday at $11.65.
According to TipRanks.com, Nierengarten is a 5-star analyst with an average return of
The word on The Street in general, suggests a Strong Buy analyst consensus rating for 2seventy bio with a $29.00 average price target, a 153.9% upside from current levels. In a report issued on May 4, SVB Securities also maintained a Buy rating on the stock with a $33.00 price target.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Read More on OM:
